Mina Allo provides strategic consulting and pragmatic solutions to life science and managed care organizations around market access, health economics and outcomes research, real-world evidence, pharmaceutical benefit design, and population health strategies.

Mina previously served in Commercial Markets at Tempus Labs, a precision medicine organization applying AI to genomic and clinical data in healthcare, where she created partnerships with commercial and Medicare Advantage payers to ensure patient access to next generation comprehensive genomic testing for oncology and pharmacogenetic diagnostics. Prior to that, Mina was at Bristol-Myers Squibb in US HEOR within the Value, Access & Payment organization, where she led collaborations across commercial, federal and provider channels around product access, medical value evaluations, real-world evidence, evidence strategy, and population health and quality improvement initiatives. Prior to Bristol-Myers Squibb, Mina led formulary management and product design, specialty drug management, and quality improvement / CMS quality performance Stars initiatives for the Medicare Advantage and Part D lines of business as clinical pharmacist at Blue Cross Blue Shield of Michigan.

Mina received her Doctor of Pharmacy from Purdue University, a Master of Public Health in epidemiology from the Harvard T.H. Chan School of Public Health, and completed a post-doctoral fellowship in US Policy and Advocacy at Rutgers University and Bristol-Myers Squibb.

Authored Content


This expert panel will address the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery.

Newly developed HCPCS codes will support increased access to oncology navigation services, which have been shown to improve patient outcomes.

ChatGPT marked an AI inflection point decades in the making—with implications for health economics and outcomes research.